SkinBioTherapeutics - Superdrug first phase of store locations

SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")

​

Superdrug first phase of store locations for AxisBiotix™ launch in the UK

​

6 October 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, has received a list of participating Superdrug Stores plc ('Superdrug') for the first phase of the AxisBiotix™ launch. AxisBiotix™ food supplements are used to alleviate the symptoms of inflammatory skin conditions.

Superdrug has informed SkinBioTherapeutics of its intention to launch the first tranche of product in stores  which typically have higher sales of medicated skincare relative to the rest of the Group. A phased roll-out to the rest of Superdrug's UK store portfolio is scheduled to commence in Spring 2026.

SkinBioTherapeutics has successfully delivered both products and approved packaging despite having been set a very short lead time by Superdrug. The placement of product on shelves is in the hands of the Superdrug commercial team, but is expected to be imminently.

In June 2025, SkinBioTherapeutics signed an exclusive UK commercial agreement with Superdrug, one of the UK's leading beauty and health retailers related to AxisBiotix™. The commercial agreement is on an exclusive basis for two years.

Stuart Ashman, CEO of SkinBioTherapeutics said:

"The agreement with Superdrug around AxisBiotix™ was SkinBioTherapeutic's first national high street agreement and a major milestone for the Company. On behalf of the leadership team, I extend my sincere thanks to the whole AxisBiotix™ team for their enormous effort in meeting the very tight deadline set by Superdrug for the manufacture and packaging and delivery of product for launch, as well as ongoing stock for the next phases of the launch next year. We are very much looking forward to seeing the product on the shelves very soon and the reception from customers."

List of stores

-Ends-   

For more information please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of inflammatory skin conditions, is sold directly and via Amazon.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

About Superdrug

Superdrug is one of the UK's leading health and beauty retailers operating in the UK and Republic of Ireland, offering a wide range of products and services, including in-store pharmacies and online doctor services. Superdrug is owned by AS Watson Group, a global health and beauty retailer. For more information, please visit the website: www.superdrug.com.